Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreas, Darian, Tosoian, Jeffrey J., Landis, Patricia, Wolf, Sacha, Glavaris, Stephanie, Lotan, Tamara L., Schaeffer, Edward M., Sokoll, Lori J., Ross, Ashley E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527/
https://www.ncbi.nlm.nih.gov/pubmed/27335798
http://dx.doi.org/10.1016/j.eucr.2016.04.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527/
https://www.ncbi.nlm.nih.gov/pubmed/27335798
http://dx.doi.org/10.1016/j.eucr.2016.04.012

Ejemplares similares